GILD - Gilead Sciences, Inc.
66.80 +0.22 (0.33%)
After hours: 6:46PM EDT
| Previous Close | 65.86 |
| Open | 65.72 |
| Bid | 66.51 x 1200 |
| Ask | 66.75 x 800 |
| Day's Range | 65.53 - 66.65 |
| 52 Week Range | 60.32 - 72.90 |
| Volume | 5,058,873 |
| Avg. Volume | 5,884,946 |
| Market Cap | 84.321B |
| Beta (3Y Monthly) | 1.19 |
| PE Ratio (TTM) | 14.43 |
| EPS (TTM) | 4.61 |
| Earnings Date | Oct 24, 2019 |
| Forward Dividend & Yield | 2.52 (3.86%) |
| Ex-Dividend Date | 2019-09-12 |
| 1y Target Est | 79.97 |
- Yahoo Finance
Amazon, Twitter, Intel earnings — What to know in markets Thursday
Tech takes the spotlight Thursday when three big names gear up to report quarterly results: Amazon, Twitter and Intel.
- Zacks
Why Gilead (GILD) Might Surprise This Earnings Season
Gilead (GILD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- Zacks
The Zacks Analyst Blog Highlights: U.S. Bancorp, Bristol-Myers Squibb, Morgan Stanley, Bank of America and Gilead Sciences
The Zacks Analyst Blog Highlights: U.S. Bancorp, Bristol-Myers Squibb, Morgan Stanley, Bank of America and Gilead Sciences
- Zacks
Will Strong Jakafi Sales Drive Incyte's (INCY) Q3 Earnings?
Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Incyte (INCY) reports third-quarter 2019 results.
- Zacks
Top Stock Reports for U.S. Bancorp, Bristol-Myers Squibb & Morgan Stanley
Top Stock Reports for U.S. Bancorp, Bristol-Myers Squibb & Morgan Stanley
- Zacks
Exact Sciences (EXAS) to Post Q3 Earnings: What's in Store?
During Exact Sciences' (EXAS) third-quarter 2019 conference call, investor focus will be on the volume growth rate of its non-invasive screening test for colorectal cancer, Cologuard.
- Zacks
What's in Store for Healthcare ETFs in Q3 Earnings?
With earnings surprise in the cards, the healthcare sector is expected to witness modest earnings growth of 0.3% in the third quarter, suggesting some room for potential upside for healthcare ETFs.
- Zacks
Will Soliris Aid Growth for Alexion (ALXN) in Q3 Earnings?
During Alexion's (ALXN) third-quarter earnings call, investor focus will be on the sales performance of its blockbuster drug Soliris along with the sales figure of Ultomiris, Strensiq and Kanuma.
- GuruFocus.com
New Gilead CFO: Let's Make a Deal
The nearly $83 billion biotech giant seems poised to supercharge its M&A; and partnership efforts Continue reading...
- Zacks
Will Strong HIV Sales Drive Gilead's (GILD) Q3 Earnings?
Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Gilead (GILD) reports third-quarter 2019 results.
- Zacks
Factors Setting the Tone for Novartis' (NVS) Q3 Earnings
Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Novartis (NVS) reports third-quarter 2019 results.
- Zacks
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Gilead Sciences (GILD) closed at $65.23, marking a -0.18% move from the previous day.
- American City Business Journals
Job hopping: This is how long employees typically stay at Tesla, Apple, Facebook, Cisco, Nvidia, Oracle and more
The typical Facebook employee stays with the company for just over 2.5 years, a Business Journal analysis shows. This is how that compares to other large Silicon Valley tech employers, like Cisco, Apple and Intel.
- Zacks
Can New Drugs Help Lilly (LLY) to Deliver Solid Q3 Earnings?
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are likely to have performed well. Let's see if these along with its older products lead to an earnings beat for the company in Q3.
- Zacks
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Biogen (BIIB) to Report Q3 Earnings: What's in the Cards?
Biogen's (BIIB) MS franchise sales are expected to have been soft in the third quarter of 2019. Spinraza U.S. sales are expected to have been supported by continued patient growth
- Barrons.com
Gilead Just Named a New CFO. Is More Deal Making on the Way?
Gilead corporate development head Andy Dickinson’s elevation to CFO means that partnerships and acquisitions will be at the center of the company’s strategy, one analyst says.
- Zacks
The Zacks Analyst Blog Highlights: Cisco Systems, SAP, Gilead Sciences, Bank of America and Caterpillar
The Zacks Analyst Blog Highlights: Cisco Systems, SAP, Gilead Sciences, Bank of America and Caterpillar
- MarketWatch
Gilead names Andrew Dickinson CFO effective Nov. 1
Gilead Sciences Inc. said Tuesday it has appointed Andrew Dickinson as chief financial officer, effective Nov. 1. Dickinson is currently executive vice president corporate development and strategy and will become a member of the senior leadership team reporting to Chief Executive Daniel O'Day. The executive joined the company in 2016 after stints at Lazard and Myogen Inc., which Gilead acquired in 20016. Shares were not yet active premarket, but have gained 3% in 2019, while the S&P 500 has gained 18%.
- Business Wire
Gilead Sciences Appoints Andrew Dickinson as Chief Financial Officer
Gilead Sciences, Inc. (GILD) today announced that Andrew Dickinson has been appointed Chief Financial Officer (CFO), effective November 1. Mr. Dickinson currently serves as the company’s Executive Vice President, Corporate Development and Strategy, and in his new role he will continue to be a member of the senior leadership team, reporting to Daniel O’Day, Chairman and Chief Executive Officer. Mr. Dickinson joined Gilead in 2016 and has transformed the way that the company approaches corporate development, expanding the kinds of transactions executed and implementing a broader and more strategic approach to deal-making.
- American City Business Journals
Why cell therapies are cancer's next frontier
South San Francisco-based Allogene is taking a different approach to cell therapy for cancer by producing so-called allogenic cell therapies.
- Zacks
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
Gilead Sciences (GILD) closed the most recent trading day at $63.99, moving +1.15% from the previous trading session.
- American City Business Journals
Startup with eye on fatty liver disease NASH lays out $70M IPO plan
A biotech company that started in Israel 21 months ago and moved to San Francisco this year wants to raise $70 million through an initial public offering to tackle one of the hottest areas of drug development. Fourteen-employee 89bio Inc. stated in a Securities and Exchange Commission filing Friday that it plans to use the cash to complete mid-stage clinical trials of its signature drug against the fatty liver disease known as nonalcoholic steatohepatitis, or NASH, and severe hypertriglyceridemia as well as for drug manufacturing. NASH has attracted deep-pocketed drug companies such as Foster City-based Gilead Sciences Inc. (NASDAQ: GILD), South San Francisco's NGM Biopharmaceuticals Inc. (NASDAQ: NGM), Pfizer Inc. (NYSE: PFE) and Intercept Pharmaceuticals Inc. (NASDAQ: ICPT) and an army of smaller companies, such as South San Francisco's Akero Therapeutics Inc. (NASDAQ: AKRO).
